Literature DB >> 9915657

State-of-the-art update and review: clinical trials of lipid-lowering agents.

P O Kwiterovich1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9915657     DOI: 10.1016/s0002-9149(98)00957-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  7 in total

Review 1.  Risks and benefits of statin use in young people with type 1 diabetes.

Authors:  Petter Bjornstad; R Paul Wadwa
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

Review 2.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 3.  Pharmacogenetics of Lipid-lowering Therapies.

Authors:  Jose M Ordovas; Haiqing Shen
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

4.  An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI.

Authors:  Xuelei Song; Paul Fischer; Xun Chen; Charlotte Burton; Jun Wang
Journal:  Int J Biol Sci       Date:  2009-10-09       Impact factor: 6.580

Review 5.  Mechanism of action of niacin on lipoprotein metabolism.

Authors:  V S Kamanna; M L Kashyap
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

Review 6.  Niacin dosing: relationship to benefits and adverse effects.

Authors:  D M Capuzzi; J M Morgan; O A Brusco; C M Intenzo
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

7.  Dyslipidemia.

Authors:  Adam M. Cohen; Daniel J. Rader
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.